Optimization of polc polymerase inhibitors for treatment of high priority gram-positive pathogens.
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN272201500012C
- Awardee
-
Crestone, Inc. UEI EDSLAP2J1BL8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,944,542
Award facts
- Opportunity
-
- NIHAI2014007 Solicitation number
- Targeting Therapeutics Development to Relieve Bottlenecks Award Notice · Posted Jun 13, 2014
- Request for Infomration (RFI) : Optimizing Lead Therapeutic Compounds Against Infectious Pathogens - Amendment 1 Award Notice · Posted Mar 21, 2014
- Contract value 100% obligated
- $5,944,542.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 26 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Boulder, CO 80301, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$6,702 | |
| Supplemental Agreement for work within scope | $81,740 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $476,563 | |
| Exercise an Option | $1,801,647 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $297,787 | |
| Exercise an Option | $1,507,181 | |
| Original award | $1,786,326 |
About this award
This is a $5,944,542.04 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, to Crestone, Inc., a biotech company in Boulder, Colorado. The contract is for the optimization of POLC polymerase inhibitors to treat high-priority gram-positive bacterial pathogens. This is a definitive contract with a period of performance ending on June 30, 2019. The contract did not have a set-aside designation. Crestone, Inc. is a for-profit organization that has received over $50 million in federal contracts and grants from NIAID and the Department of Veterans Affairs to support its research on novel treatments for antibiotic-resistant infections, including Clostridioides difficile and Helicobacter pylori.
Quick answers
Who was awarded contract HHSN272201500012C?
HHSN272201500012C was awarded to Crestone, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 27, 2015.
How much is contract HHSN272201500012C worth?
The government has obligated $5,944,542 on HHSN272201500012C.
Was contract HHSN272201500012C competed?
The extent of competition for HHSN272201500012C was full and open competition. The government received 26 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award